Susannah L McKay1,2, Angela Guo2, Steven A Pergam3,4,5,6, Kathleen Dooling2. 1. Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. 2. Division of Viral Diseases, National Center Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. 3. Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA. 4. Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA. 5. Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA. 6. Infection Prevention, Seattle Cancer Care Alliance, Seattle, Washington, USA.
Abstract
BACKGROUND: The primary reported risk factors for herpes zoster (HZ) include increasing age and immunodeficiency, yet estimates of HZ risk by immunocompromising condition have not been well characterized. We undertook a systematic literature review to estimate the HZ risk in immunocompromised patients. METHODS: We systematically reviewed studies that examined the risk of HZ and associated complications in adult patients with hematopoietic cell transplants (HCT), cancer, human immunodeficiency virus (HIV), and solid organ transplant (SOT). We identified studies in PubMed, Embase, Medline, Cochrane, Scopus, and clinicaltrials.gov that presented original data from the United States and were published after 1992. We assessed the risk of bias with Cochrane or Grading of Recommendations Assessment, Development, and Evaluation methods. RESULTS: We identified and screened 3765 records and synthesized 34 studies with low or moderate risks of bias. Most studies that were included (32/34) reported at least 1 estimate of the HZ cumulative incidence (range, 0-41%). There were 12 studies that reported HZ incidences that varied widely within and between immunocompromised populations. Incidence estimates ranged from 9 to 92 HZ cases/1000 patient-years and were highest in HCT, followed by hematologic malignancies, SOT, and solid tumor malignancies, and were lowest in people living with HIV. Among 17 HCT studies, the absence of or use of antiviral prophylaxis at <1 year post-transplant was associated with a higher HZ incidence. CONCLUSIONS: HZ was common among all immunocompromised populations studied, exceeding the expected HZ incidence among immunocompetent adults aged ≥60 years. Better evidence of the incidence of HZ complications and their severity in immunocompromised populations is needed to inform economic and HZ vaccine policies. Published by Oxford University Press for the Infectious Diseases Society of America 2019.
BACKGROUND: The primary reported risk factors for herpes zoster (HZ) include increasing age and immunodeficiency, yet estimates of HZ risk by immunocompromising condition have not been well characterized. We undertook a systematic literature review to estimate the HZ risk in immunocompromised patients. METHODS: We systematically reviewed studies that examined the risk of HZ and associated complications in adult patients with hematopoietic cell transplants (HCT), cancer, humanimmunodeficiency virus (HIV), and solid organ transplant (SOT). We identified studies in PubMed, Embase, Medline, Cochrane, Scopus, and clinicaltrials.gov that presented original data from the United States and were published after 1992. We assessed the risk of bias with Cochrane or Grading of Recommendations Assessment, Development, and Evaluation methods. RESULTS: We identified and screened 3765 records and synthesized 34 studies with low or moderate risks of bias. Most studies that were included (32/34) reported at least 1 estimate of the HZ cumulative incidence (range, 0-41%). There were 12 studies that reported HZ incidences that varied widely within and between immunocompromised populations. Incidence estimates ranged from 9 to 92 HZ cases/1000 patient-years and were highest in HCT, followed by hematologic malignancies, SOT, and solid tumor malignancies, and were lowest in people living with HIV. Among 17 HCT studies, the absence of or use of antiviral prophylaxis at <1 year post-transplant was associated with a higher HZ incidence. CONCLUSIONS: HZ was common among all immunocompromised populations studied, exceeding the expected HZ incidence among immunocompetent adults aged ≥60 years. Better evidence of the incidence of HZ complications and their severity in immunocompromised populations is needed to inform economic and HZ vaccine policies. Published by Oxford University Press for the Infectious Diseases Society of America 2019.
Authors: Adriana Bastidas; Javier de la Serna; Mohamed El Idrissi; Lidia Oostvogels; Philippe Quittet; Javier López-Jiménez; Filiz Vural; David Pohlreich; Tsila Zuckerman; Nicolas C Issa; Gianluca Gaidano; Je-Jung Lee; Sunil Abhyankar; Carlos Solano; Jaime Perez de Oteyza; Michael J Satlin; Stefan Schwartz; Magda Campins; Alberto Rocci; Carlos Vallejo Llamas; Dong-Gun Lee; Sen Mui Tan; Anna M Johnston; Andrew Grigg; Michael J Boeckh; Laura Campora; Marta Lopez-Fauqued; Thomas C Heineman; Edward A Stadtmauer; Keith M Sullivan Journal: JAMA Date: 2019-07-09 Impact factor: 56.272
Authors: S Bilgrami; N G Chakraborty; F Rodriguez-Pinero; A M Khan; J M Feingold; R D Bona; R L Edwards; D Dorsky; J Clive; B Mukherji; P J Tutschka Journal: Bone Marrow Transplant Date: 1999-03 Impact factor: 5.483
Authors: P McLaughlin; F B Hagemeister; J E Romaguera; A H Sarris; O Pate; A Younes; F Swan; M Keating; F Cabanillas Journal: J Clin Oncol Date: 1996-04 Impact factor: 44.544
Authors: Barbara P Yawn; Patricia Saddier; Peter C Wollan; Jennifer L St Sauver; Marge J Kurland; Lina S Sy Journal: Mayo Clin Proc Date: 2007-11 Impact factor: 7.616
Authors: Mindy G Schuster; Angela A Cleveland; Erik R Dubberke; Carol A Kauffman; Robin K Avery; Shahid Husain; David L Paterson; Fernanda P Silveira; Tom M Chiller; Kaitlin Benedict; Kathleen Murphy; Peter G Pappas Journal: Open Forum Infect Dis Date: 2017-03-22 Impact factor: 3.835
Authors: Laura P Hurley; Sean T O'Leary; Kathleen Dooling; Tara C Anderson; Lori A Crane; Jessica R Cataldi; Michaela Brtnikova; Brenda L Beaty; Carol Gorman; Angela Guo; Megan C Lindley; Allison Kempe Journal: J Gen Intern Med Date: 2022-07-06 Impact factor: 6.473
Authors: Alain Makinson; Lesley S Park; Kimberly Stone; Janet Tate; Maria C Rodriguez-Barradas; Sheldon T Brown; Roxanne Wadia; Kristina Crothers; Roger Bedimo; Matthew Bidwell Goetz; Fatma Shebl; Jacques Reynes; Vincent Le Moing; Keith M Sigel Journal: Open Forum Infect Dis Date: 2021-07-19 Impact factor: 3.835